iRhythm Technologies, Inc. (IRTC) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects strong financial performance with improved operational efficiency and positive free cash flow, despite minor uncertainties in FDA timelines. Raised revenue guidance and optimistic growth in core and innovative channels, combined with strategic investments in innovation and market expansion, indicate a positive outlook. However, management's lack of clarity on some future plans tempers the sentiment slightly, but overall, positive elements outweigh the negatives, suggesting a positive stock price reaction.
Key Financial Performance
Revenue $192.9 million, representing year-over-year growth of 31%. This growth was driven by record performance in Zio Monitor and Zio AT, primary care expansion, innovative health channels, and new EHR integrations.
Gross Margin 71.1%, an improvement of 230 basis points compared to the third quarter of 2024. This was driven by volume leverage and operational efficiencies, offsetting higher blended cost per unit from increased Zio AT product mix.
Adjusted Operating Expenses $141.4 million compared to $143.8 million in Q3 2024. Excluding a $32.1 million charge in Q3 2024, the increase was due to volume-related costs and investments for growth. Adjusted operating expenses as a percentage of revenue improved due to efficiency initiatives.
Adjusted Net Loss $2 million, or $0.06 per share, compared to $39.2 million, or $1.26 per share, in Q3 2024. This improvement reflects better operational performance and cost management.
Adjusted EBITDA $21.6 million, or 11.2% of revenue, compared to negative 13.5% in Q3 2024. Excluding IPR&D expenses, Q3 2024 adjusted EBITDA margin would have been 8.3%, showing a 300 basis point improvement year-over-year.
Free Cash Flow $20.0 million, marking the third consecutive quarter of trailing 12-month positive free cash flow generation. This reflects sustainable efficiencies and investments in growth initiatives.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Zio Monitor and Zio AT: Achieved record performance, contributing to a 31% year-over-year revenue growth in Q3 2025. Zio AT saw year-over-year unit growth more than double the corporate average.
Zio MCT: Submitted 510(k) filing for next-generation mobile cardiac telemetry solution with advanced features like 21-day wear and improved detection algorithms.
AI-driven solutions: Advancing AI prediagnostic and diagnostic pathways for sleep apnea and arrhythmia detection, with promising pilot results in identifying undiagnosed cardiac arrhythmias.
Primary care expansion: Strong progress in using Zio as a rule-in or rule-out tool for earlier intervention, improving patient outcomes and reducing specialist bottlenecks.
International expansion: Growth in Japan with 13 systems live and positive physician feedback. In Europe, strong growth in the U.K. private market and presence in 4 EU countries, supported by clinical evidence.
Innovative channel partnerships: 18 active partner accounts targeting large undiagnosed arrhythmia populations, with a healthy pipeline of additional partnerships under discussion.
EHR integration: 76 of the top 100 customers are EHR integrated, with 30 systems live on Epic Aura. EHR integration has led to a 25% increase in monitoring volume within 6 months of going live.
Operational efficiencies: Achieved gross margin improvement to 71.1% in Q3 2025, driven by volume leverage and operational efficiencies.
Free cash flow: Generated positive free cash flow for the first time on an annual basis, marking a significant milestone in financial sustainability.
AI and data-driven evolution: Partnership with Lucem Health to advance clinical AI capabilities, aiming to transition from a device-enabled service to a comprehensive digital health platform.
Adjacent market expansion: Exploring sleep apnea as a complementary market, leveraging clinical overlap with arrhythmia and cardiovascular disease.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Challenges: The company faces potential risks related to FDA remediation expenses and the review process for new product submissions, such as the 510(k) filing for Zio MCT. These regulatory hurdles could delay product launches or increase costs.
Tariff Impacts: Tariffs on global imports are expected to negatively impact gross margins by approximately 50 basis points for the full year 2025, adding financial pressure.
Market Competition: Despite strong clinical evidence, the company faces competition from short-duration Holter and event monitors, which still represent a significant portion of the market. This could limit market share growth.
Economic and Operational Efficiency Risks: While the company is focused on driving productivity gains and improving efficiencies, there is a risk that these initiatives may not yield the expected results, potentially impacting profitability.
Supply Chain and Cost Pressures: Higher blended cost per unit due to increased Zio AT product mix could offset operational efficiencies, impacting overall profitability.
International Expansion Risks: Efforts to expand in Japan and Europe involve uncertainties, including the need for differentiated reimbursement and competition with local cardiac monitoring devices. These factors could hinder international growth.
Strategic Execution Risks: The company’s ambitious plans to scale AI-driven solutions and expand into adjacent markets like sleep apnea carry execution risks, including the ability to validate and commercialize these innovations effectively.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: iRhythm raised its full-year 2025 revenue guidance to $735 million to $740 million, representing 24% to 25% year-over-year growth. This includes expectations of continued strong volume growth and a low single-digit pricing tailwind.
Gross Margin Outlook: The company anticipates full-year 2025 gross margin to slightly exceed 2024 levels, with clinical operations and manufacturing efficiencies offsetting tariff impacts. Tariffs are expected to negatively impact gross margin by approximately 50 basis points for the full year.
Adjusted EBITDA Margin Guidance: iRhythm raised its full-year adjusted EBITDA margin guidance to 8.25% to 8.75% of revenues. This includes absorption of acquired IPR&D expenses, tariff impacts, and FDA remediation expenses.
Free Cash Flow: The company expects to be slightly free cash flow positive for full-year 2025, marking a significant milestone in its financial performance.
Future Growth and Investments: iRhythm plans to continue investing in growth initiatives, infrastructure scalability, and next-generation technology platforms to sustain profitable growth into 2026 and beyond.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What has been driving the new account openings and volume growth in the core Zio Monitor business?
A:The growth is driven by new accounts onboarding, the ability to scale and absorb the entire network of customers on day 1, and new accounts bringing their entire long-term cardiac monitor business, including MCT business with AT. The quality and size of new accounts have improved, and there is a combination of market share shift and overall market growth.
Q:What is driving the outperformance expected in Q4?
A:The outperformance is primarily tied to Zio Monitor, with healthy growth expected from both AT and innovative channels. Most of the raise in guidance is attributable to Monitor, with good contributions across different businesses.
Q:How should we think about growth cadence for MCT with its potential approval next year?
A:The company is planning for MCT to launch in the back half of next year, but without clear FDA approval timelines, expectations for 2026 do not include MCT contributions. The company is bullish on converting market share within the MCT category, aiming to grow from a 13% market share to 25%-35%.
Q:What is the sales cycle and penetration level for the innovative partner channel?
A:The sales cycle varies by customer, ranging from 90 days to over a year. The company has 18 customers in the innovative channel, up from 12 in Q2. The penetration level and contribution from this channel are growing, but the company is cautious about setting specific expectations due to variability in the sales process.
Q:What are the updates on FDA remediation efforts for the warning letter and 483s?
A:The FDA has asked the company to put remediation efforts on hold during the government shutdown. The company has completed internal remediation efforts and launched an external review of quality systems by an independent third party, which is progressing well.
Q:What is the incremental patient pool in the innovative channels, and how durable is this channel?
A:The innovative channels target asymptomatic, undiagnosed populations, with a focus on comorbid disease states like type 2 diabetes, COPD, and CKD. The channel is durable due to the economic benefits of proactive monitoring, such as reduced ER visits and hospital stays.
Q:What is the margin trajectory and investment priorities as the company transitions to free cash flow positive?
A:The company expects gross margins to reach 72%-73% by 2027, with adjusted EBITDA expanding by 400 basis points annually. Investments are focused on innovation (e.g., Zio MCT, multi-vitals platform, sleep diagnostics) and operational efficiencies, including AI integration.
Q:What is the strategy for entering the sleep diagnostics market?
A:The company aims to leverage its existing platform for sleep diagnostics, potentially diagnosing sleep disorders using the same form factor as Zio MCT. Pilots are launching, and a diagnostic product is expected in a few years.
Q:What is the impact of EHR integration on account utilization?
A:EHR integration, particularly with Epic, increases account utilization by 25% within six months post-integration. It simplifies workflows, enables primary care physicians to prescribe devices, and ensures seamless data sharing within integrated systems.
Q:What is the launch strategy for Zio MCT once approved?
A:The launch strategy will focus on closing gaps with customers not currently working with iRhythm due to duration limitations. The downgradable aspect of Zio MCT will be at the company's discretion, and commercialization plans are still being finalized.
Q:Review of Unclear Management Responses
A:Management avoided providing clear timelines or specific details on the FDA approval process for MCT, the exact commercialization strategy for the downgradable aspect of Zio MCT, and the specific financial impact of innovative channels and sleep diagnostics. They also did not provide clarity on the exact size of the incremental patient pool in innovative channels or the detailed financial outlook for 2026.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AFib
AI
EHR integration
EHR system
UK
Zio term
accuracy
adoption
analysis patient
apnea literature
arrhythmia solution
cash flow
condition risk
detection
discussion
efficiency infrastructure
event health
flow generation
head
health care
increase volume
individual
outcome
overlap
partnership
pathway
patient sleep
potential
profitability profile
record Zio
reduction
sleep apnea
stay
strength
study
system physician
tariff
term monitoring
utilization
visit
world analysis
IRTC Transcript
iRhythm Holdings, Inc. (IRTC) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
iRhythm Holdings, Inc. (IRTC) Q1 2026 Earnings Call Transcript
Positive5-1
The earnings call summary reveals a strong financial performance with a 22% YoY revenue increase, improved gross margins, and a reduced net loss. Despite increased operating expenses, the significant improvement in adjusted EBITDA indicates effective cost management. The absence of negative sentiment or critical issues in the Q&A section supports a positive outlook. Given the company's market cap, these factors are likely to result in a positive stock price movement of 2% to 8% over the next two weeks.
i-80 Gold Corp. (IAU:CA) Q4 2025 Earnings Call Transcript
Unknown2-20
The earnings call reflects several challenges: increased operational expenses, permitting delays, and heavy reliance on financing, which strain cash flows. Despite achieving production guidance and increased gold sales, the net loss widened significantly. The Q&A session revealed unclear management responses and a lack of detailed cost information, further clouding the outlook. These factors, combined with economic uncertainties and operational risks, suggest a negative sentiment, likely leading to a stock price decline of -2% to -8% over the next two weeks.
iRhythm Holdings, Inc. (IRTC) Q4 2025 Earnings Call Transcript
Positive2-20
The earnings call summary and Q&A reveal positive financial performance with strong revenue growth, improved margins, and positive free cash flow. The company's strategic initiatives, including partnerships and technological advancements, are well-received, despite some uncertainties in guidance. The Q&A reflects optimism about future growth and the impact of CMS proposals, AI, and wearables. The stock market cap indicates a moderate reaction, suggesting a positive stock price movement of 2% to 8% over the next two weeks.
IRTC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
